Search Results

You are looking at 1 - 10 of 120 items for :

  • "carcinoma in situ" x
Clear All
Full access

Adam L. Cohen and John H. Ward

D uctal carcinoma in situ (DCIS) is “a proliferation of malignant epithelial cells within the breast parenchymal structures with no evidence of invasion across the basement membrane.” 1 It is one fourth as common as invasive breast cancer, with

Full access

Stephen B. Edge and David G. Sheldon

ductal carcinoma in situ patients . Ann Surg Oncol 2000 ; 7 : 15 – 20 . 2 Cox CE Nguyen K Gray RJ . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001 ; 67 : 513 – 519 . 3 Klauber

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag and Rinaa S. Punglia

As the incidence of ductal carcinoma in situ (DCIS) has increased, so has the number of DCIS survivors. 1 Most patients with DCIS are treated with breast-conserving surgery (BCS). 2 Radiation therapy (RT) and antiestrogen therapy (AET) have been

Full access

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor and Courtney Vito

Background Ductal carcinoma in situ (DCIS) is a premalignant breast lesion that has been increasingly diagnosed in the era of screening mammography, 1 and accounts for 20% to 25% of all new breast cancer diagnoses. 2 Marked atypia may be

Full access

Nalan Nese, Ruta Gupta, Matthew H. T. Bui and Mahul B. Amin

Edited by Kerrin G. Robinson

Novartis, Inc. References 1 Sesterhenn IA . Urothelial carcinoma in situ . In: Eble J Sauter G Epstein J Sesterhenn I , eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde and Benjamin O. Anderson

In both the medical literature and lay press, a flurry of controversy has arisen surrounding the treatment and, more specifically, the potential overtreatment of ductal carcinoma in situ (DCIS). Since the advent of population-based screening

Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin and Rinaa S. Punglia

Background Women with a history of ductal carcinoma in situ (DCIS) are at increased risk for developing a second breast cancer (SBC) in either the ipsilateral or contralateral breast. 1 , 2 Many women receive breast-conserving surgery (BCS) with

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor and Abenaa M. Brewster

Breast Cancer Prevention Trial (BCPT) enrolled women based on either age of 60 years or older, or age 35 to 59 years with a modified Gail model 5-year predicted risk of breast cancer of 1.66% or greater or a history of lobular carcinoma in situ (LCIS

Full access

Amy Ly, Jill C. Ono, Kevin S. Hughes, Martha B. Pitman and Ronald Balassanian

situ (ALH/LCIS), fibromatosis, unclassified fibroepithelial lesion, and nonmalignant Phyllodes tumors. Malignant cases contained ductal carcinoma in situ (DCIS) with and without associated invasive breast carcinoma (IBC). Fifty MGH-FNAB cases were

Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang and Cary P. Gross

) invasive breast cancer irrespective of tumor size. Based on the 2009 guidelines, women with 1 to 3 positive axillary nodes were considered guideline-discordant. We excluded patients with ductal carcinoma in situ, localized HR+, node-negative, ≤5 mm